Literature DB >> 27080140

Clinical characteristics and outcomes of oropharyngeal carcinoma related to high-risk non-human papillomavirus16 viral subtypes.

Indu Varier1, Brieze R Keeley2, Rosemarie Krupar1, Alexis Patsias2,3, Joanna Dong2, Nikita Gupta2, Arjun K Parasher2, Eric M Genden2, Brett A Miles2, Marita Teng2, Richard L Bakst4, Vishal Gupta4, Krzysztof J Misiukiewicz5, Elizabeth Y Chiao6,7, Michael E Scheurer8, Simon Laban9, David Zhang10, Fei Ye10, Miao Cui10, Elizabeth G Demicco10, Marshall R Posner5, Andrew G Sikora1.   

Abstract

BACKGROUND: The majority of human papillomavirus (HPV)-related oropharyngeal carcinomas (OPCs) are associated with HPV genotype 16; however, OPC can be associated with other high-risk non-HPV16 genotypes.
METHODS: This was a retrospective analysis of patients with high-risk non-HPV16 OPC treated at a single tertiary institution. Sociodemographic and clinical information was obtained by chart review. HPV genotype was determined by polymerase chain reaction (PCR). Baseline data and outcomes were compared between HPV16 and high-risk non-HPV16 groups.
RESULTS: High-risk non-HPV16 genotypes accounted for 9% of HPV-related OPC. Of the 27 total high-risk non-HPV16 OPCs, HPV35 was most prevalent (48%). High-risk non-HPV16 OPC presented at a slightly higher age (p = .021) and higher clinical T classification (p = .008) compared to HPV16 OPC, but there was no significant survival difference.
CONCLUSION: Clinical characteristics of high-risk non-HPV16 OPC were largely consistent with those of HPV16 OPC. Additional multi-institutional studies will be required to demonstrate conclusively that the favorable prognosis of patients with HPV16 applies to all high-risk HPV types.
© 2016 Wiley Periodicals, Inc. Head Neck 38: 1330-1337, 2016. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  genotypes; head and neck squamous cell carcinoma; human papillomavirus (HPV); oropharyngeal cancer

Mesh:

Substances:

Year:  2016        PMID: 27080140     DOI: 10.1002/hed.24442

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  11 in total

1.  Human papillomavirus in oropharyngeal squamous cell carcinoma in South-Eastern Norway: prevalence, genotype, and survival.

Authors:  Guro Haugen Fossum; Agnes Kathrine Lie; Peter Jebsen; Lars Erik Sandlie; Jon Mork
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-09-20       Impact factor: 2.503

2.  Prognostic significance of non-HPV16 genotypes in oropharyngeal squamous cell carcinoma.

Authors:  Angela L Mazul; Nidia Rodriguez-Ormaza; James M Taylor; Dipan D Desai; Paul Brennan; Devasena Anantharaman; Tarik Gheit; Massimo Tommasino; Behnoush Abedi-Ardekani; Andrew F Olshan; Jose P Zevallos
Journal:  Oral Oncol       Date:  2016-09-06       Impact factor: 5.337

3.  HPV33+ HNSCC is associated with poor prognosis and has unique genomic and immunologic landscapes.

Authors:  Kate Chatfield-Reed; Shanying Gui; Wendi Q O'Neill; Theodoros N Teknos; Quintin Pan
Journal:  Oral Oncol       Date:  2019-12-10       Impact factor: 5.337

4.  Distinct biomarker and behavioral profiles of human papillomavirus-related oropharynx cancer patients by age.

Authors:  Carole Fakhry; Tim Waterboer; William H Westra; Lisa M Rooper; Melina Windon; Tanya Troy; Wayne Koch; Christine G Gourin; Noemi Bender; Siddhartha Yavvari; Ana P Kiess; Brett A Miles; William R Ryan; Patrick K Ha; David W Eisele; Gypsyamber D'Souza
Journal:  Oral Oncol       Date:  2019-12-24       Impact factor: 5.337

5.  Prognostic factors for human papillomavirus-positive and negative oropharyngeal carcinomas.

Authors:  Linda X Yin; Gypsyamber D'Souza; William H Westra; Steven J Wang; Annemieke van Zante; Yuehan Zhang; Eleni M Rettig; William R Ryan; Patrick K Ha; Alicia Wentz; Wayne Koch; David W Eisele; Carole Fakhry
Journal:  Laryngoscope       Date:  2018-03-14       Impact factor: 3.325

Review 6.  cfDNA detection for HPV+ squamous cell carcinomas.

Authors:  Kate Chatfield-Reed; Veronique P Roche; Quintin Pan
Journal:  Oral Oncol       Date:  2021-02-11       Impact factor: 5.337

7.  Tanshinone IIA inhibits glucose metabolism leading to apoptosis in cervical cancer.

Authors:  Zhigang Liu; Wenhe Zhu; Xiangyu Kong; Xi Chen; Xinyi Sun; Wei Zhang; Ruowen Zhang
Journal:  Oncol Rep       Date:  2019-08-27       Impact factor: 3.906

8.  Comparing Outcomes for Patients with Human Papillomavirus (HPV) Type 16 versus Other High-Risk HPV Types in Oropharyngeal Squamous Cell Carcinoma.

Authors:  Rachel F Shenker; Nelson H May; Joshua D Waltonen; Jae Paul Yang; Stacey S O'Neill; Bart A Frizzell; Kathryn M Greven; Ryan T Hughes
Journal:  Head Neck Pathol       Date:  2021-02-22

Review 9.  Emerging insights into recurrent and metastatic human papillomavirus-related oropharyngeal squamous cell carcinoma.

Authors:  Farhoud Faraji; David W Eisele; Carole Fakhry
Journal:  Laryngoscope Investig Otolaryngol       Date:  2017-01-17

Review 10.  Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001.

Authors:  Brett Miles; Howard P Safran; Bradley J Monk
Journal:  Gynecol Oncol Res Pract       Date:  2017-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.